What medications are recommended for treating cardiac amyloidosis, including both transthyretin (ATTR) and light‑chain (AL) types?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Medications for Cardiac Amyloidosis

For ATTR cardiac amyloidosis, tafamidis is the FDA-approved standard of care, while for AL cardiac amyloidosis, daratumumab combined with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) is the established first-line treatment. 1

ATTR Cardiac Amyloidosis (ATTR-CM)

Disease-Modifying Therapy

Tafamidis is the only FDA-approved medication specifically for ATTR-CM and remains the cornerstone therapy 1, 2. This TTR stabilizer prevents the dissociation of transthyretin tetramers, thereby blocking fibril formation.

Acoramidis, another TTR stabilizer, has very recently received FDA approval following positive results in the ATTRibute-CM trial 2. This represents an important new option for ATTR-CM patients.

Emerging therapies currently in clinical trials include:

  • Vutrisiran (TTR gene silencer): Demonstrated efficacy in the HELIOS-B trial and awaits FDA review 2
  • Eplontersen: The CARDIO-TTRansform trial results are expected by late 2025 2
  • NTLA-2001: A CRISPR-Cas9 gene editing therapy in development 2
  • Fibril depleters: ALXN2220 and coramitug are advancing in clinical trials 2

Important Caveats for ATTR-CM

The TTR silencers (patisiran, inotersen, vutrisiran) are only FDA-approved for ATTRv polyneuropathy, NOT for cardiac disease 1. While they may be used off-label in some centers for cardiac involvement, tafamidis remains the only approved cardiac-specific therapy.

There is no evidence that TTR stabilizers or silencers benefit ATTRwt-associated polyneuropathy 1.

AL Cardiac Amyloidosis (AL-CM)

First-Line Therapy

Daratumumab plus CyBorD (cyclophosphamide, bortezomib, dexamethasone) is the standard of care for newly diagnosed AL amyloidosis 1. The landmark ANDROMEDA trial demonstrated unprecedented deep hematologic responses:

  • 78.5% achieved very good partial response or better with Dara-CyBorD
  • 49.2% with CyBorD alone
  • Daratumumab is the only FDA-approved agent specifically for AL amyloidosis 1

Treatment Algorithm by Cardiac Severity

For transplant-eligible patients (approximately 25% of newly diagnosed cases):

  • Induction with 2-4 cycles of bortezomib-based regimen
  • Followed by high-dose melphalan with autologous stem cell transplant (HDM/SCT)
  • Treatment-related mortality ~3% in experienced centers
  • Median survival >15 years in complete responders 1

Transplant contraindications include:

  • EF <40% (risk of hemodynamic decompensation) 1
  • Advanced cardiac involvement
  • Inability to tolerate fluid shifts and potential infections

For non-transplant candidates (majority of patients):

  • Daratumumab-CyBorD as standard 1
  • Alternative: Bortezomib-melphalan-dexamethasone 1

For advanced cardiac involvement (NT-proBNP >8,500 pg/mL):

  • Single-agent daratumumab with minimal dexamethasone to minimize cardiotoxicity 1

Emerging AL Therapies

Novel approaches under investigation include 2:

  • CAR-T cells and bispecific antibodies (teclistimab)
  • Birtamimab: Improved survival in advanced AL-CM during VITAL trial; under investigation in AFFIRM-AL
  • Anselamimab: In phase III CARES trials
  • AT-02: Early-phase testing for both ATTR-CM and AL-CM

Critical Monitoring Requirements

For AL Amyloidosis Treatment Response

Hematologic response criteria 1:

  • Complete response: Negative serum/urine immunofixation AND normal FLC ratio
  • Very good partial response: dFLC <40 mg/L
  • Partial response: dFLC decrease ≥50%

Cardiac response: NT-proBNP decrease >30% and <300 ng/L (if baseline >650 ng/L) 1

For TTR Silencer Therapy (if used for neuropathy)

All TTR silencers require vitamin A supplementation 3,000 IU daily (TTR transports retinol) 1

Patisiran-specific:

  • Premedication required: dexamethasone 10 mg IV, acetaminophen 500 mg, diphenhydramine 50 mg, famotidine 20 mg (at least 60 minutes before infusion) 1

Inotersen-specific:

  • Weekly platelet counts (risk of thrombocytopenia)
  • Serum creatinine and urine protein-creatinine ratio every 2 weeks (risk of glomerulonephritis) 1

Common Pitfalls to Avoid

  1. Do not use ACE inhibitors or ARBs in cardiac amyloidosis - these patients have restrictive physiology and cannot tolerate afterload reduction
  2. Do not delay treatment in AL amyloidosis - cardiac involvement portends poor prognosis without rapid hematologic response
  3. Do not confuse neuropathy approvals with cardiac approvals - TTR silencers are not FDA-approved for ATTR-CM
  4. Do not use standard heart failure medications - beta-blockers and calcium channel blockers are poorly tolerated due to negative inotropic effects in restrictive cardiomyopathy

References

2
Research

New therapies to treat cardiac amyloidosis.

Current opinion in cardiology, 2025

Related Questions

A 70‑year‑old man experiences brief facial flushing and dizziness when bending forward or standing up from a seated position, without nausea, vomiting, or other symptoms; his examination shows normal seated and standing blood pressure and heart rate and otherwise normal findings. What is the likely cause and how should it be managed?
In a 71‑year‑old woman with a very high atypical P‑ANCA (perinuclear anti‑neutrophil cytoplasmic antibodies) titer, markedly elevated free κ and λ light chains, increased γ‑globulin and total globulin, what is the likely diagnosis and what diagnostic work‑up and initial treatment should be pursued?
In a 79-year-old man presenting with shoulder and neck pain, sinus pressure above and below the eyes, left lower back pain worsened by deep inspiration, hypothermia, hypertension, and warm extremities, what emergent diagnosis should be considered and what immediate management is indicated?
What is the significance of a non‑dependent air‑fluid level in the bladder on computed tomography, and what diagnostic and therapeutic steps should be taken?
For a 52‑year‑old woman presenting with 24‑hour right‑upper‑quadrant pain, jaundice, pale stools and dark urine, what is the initial diagnostic work‑up, the three most likely differential diagnoses, the anatomy of the biliary tree, the name and management of the acute deterioration with rigors, hypotension and confusion, and the definitive surgical procedure with three key consent points?
What is the recommended eltrombopag dosing and monitoring strategy for a patient with myelodysplastic syndrome and thrombocytopenia?
Why should albumin be administered before furosemide, with furosemide given approximately 30 minutes later?
What oral antibiotic alternatives are appropriate for a patient who is allergic to clindamycin?
Is gynecomastia surgery performed under general anesthesia?
I noticed tea‑colored urine within an hour after an IV iron infusion; does this indicate hematuria and what evaluation is required?
Does tea-colored urine after an intravenous iron infusion indicate reduced iron absorption?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.